Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs) EQUITY
$99.73
neg -1.30
-1.30%
Today's Range: 99.51 - 104.49 | ALXN Avg Daily Volume: 2,169,900
Last Update: 05/25/17 - 2:04 PM EDT
Volume: 4,336,051
YTD Performance: -17.38%
Open: $104.36
Previous Close: $101.08
52 Week Range: $110.56 - $205.29
Oustanding Shares: 224,556,542
Market Cap: 23,497,596,555
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 12 12 13
Moderate Buy 1 1 1 1
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.72 1.68 1.68 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 49.83
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
49.83 50.10 29.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-23.16% -31.08% -37.72%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.40 1.00 0.25
Net Income 176.30 0.60 0.16
EPS 162.70 0.40 0.11
Earnings for ALXN:
EBITDA 1.19B
Revenue 3.08B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $1.10 $1.15 $4.49 $5.51
Number of Analysts 1 1 1 1
High Estimate $1.10 $1.15 $4.49 $5.51
Low Estimate $1.10 $1.15 $4.49 $5.51
Prior Year $0.93 $1.18 $3.78 $4.49
Growth Rate (Year over Year) 18.28% -2.54% 18.78% 22.72%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
"If you work for a living, why do you kill yourself working?" -- Tuco,
If you want to stay active, you'll have to do more homework.
"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, "
It is hard to keep up with the flurry of first-quarter earnings reports hitting the wires this morning. Here are a few that caught my eye today.
These companies show signs of a change of direction.
Even among the losers, buys are scarce.
Bullish
Nov 29, 2016 | 7:48 AM EST
ALXN was upgraded from Equal-weight to Overweight, Barclays said. $155 price target. Company has multiple potential catalysts for 2017....
Here's a window into what institutional investors may be doing and how to profit from that.
Bullish
Oct 28, 2016 | 8:02 AM EDT
ALXN was upgraded from Neutral to Buy, Goldman Sachs said. $158 price target. '1210 product could be more effective and have different ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.